Avacincaptad pegol is an RNA aptamer inhibiting the complement C5 indicated for the treatment of geographic atrophy secondary to age-related macular degeneration. Avacincaptad pegol is an RNA aptamer covalently bound to a branched polyethylene glycol (PEG) molecule.
- Mechanism
- Curator reviewed · 1 reference
Avacincaptad pegol is an RNA aptamer, a PEGylated oligonucleotide that binds to and inhibits complement protein C5. By inhibiting C5, avacincaptad pegol may prevent its cleavage to C5a and C5b thus decreasing membrane attack complex (MAC) formation.
- Primary indication
- Avacincaptad pegol is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).Curator reviewed · 1 structured indication
- First approval
- United States, 2023
- Brand names
Resolves to
Compound
Clinical / RWD
Targets
What you can answer from here — as of September 12, 2026
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Avacincaptad pegol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account